ARCHIVES

Memorial’s Scher Warns FDA About Flaws In Provenge Data, Urges Not To Approve.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials

December 31, 2004

FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer

July 27, 2012

In Brief: NCI To Go Along With NCAB on Keeping Clinical Education Program Alive; Cal Baldwin Retires

February 28, 1986

Mammography Screening Effective In Women Under 50: BCDDP

September 25, 1987

Survey Commissioned By Cancer Control Program Finds Important RMP Effort Being Phased Out

July 19, 1974

Letter: No Intent To Link Flags With NSABP Inquiry, ORI’s Bivens Writes

March 10, 1995